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Results: Locoregional recurrence was significantly lower in 
the short time-interval group (Fig. 1). Recurrence rate at 2 
years was 11% (95%CI 3-36%) in the short time-interval group 
compared to 49% (95%CI 30-73%) in the long time-interval 
group. The stepwise Cox regression identified time-interval 
(a short interval is better), T90 (higher temperatures are 
beneficial) and age (younger age is unfavourable) as 
significant prognostic factors, and shows a favourable trend 
for lower FIGO stage (Table 1). 
Overall survival was also significantly better in the short 
time-interval group (Fig. 1). Overall survival at 2 years was 
60% (95%CI 39-75%) in the short group compared to 39% 
(95%CI 21-56%) in the long time-interval group. The stepwise 
Cox regression identifies a short time-interval and higher T90 
as significant factors for a favourable outcome (Table 1). 
 
 
 
Fig. 1. Kaplan-Meier curves for locoregional recurrence (left) 
and overall survival (right) after EBRT and HT for advanced 
cervical cancer, grouped by time-interval between EBRT and 
HT. 
Table 1 Results of the Cox multivariable analysis of 
locoregional recurrence and survival after radiotherapy and 
hyperthermia for advanced cervical cancer. 
 
 
 
Conclusion: A short time interval between EBRT and HT 
results in a significantly lower recurrence and better overall 
survival for locally advanced cervical cancer patients. 
Furthermore, a higher tumour temperature during HT is 
associated with lower locoregional recurrence and better 
overall survival, stressing the importance of HT quality 
assurance. 
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Purpose or Objective: To define the recommended dose in 
high-intermediate risk endometrial cancer (HIR-EC) patients 
postoperatively irradiated by simultaneous integrated boost 
volumetric modulated arc therapy (SIB-VMAT). 
 
Material and Methods: A radiation dose of 45 Gy over 5 
weeks, 1.8 Gy/fraction, was delivered to the vagina and the 
lymphatic drainage (planning target volume, PTV2). Radiation 
dose was escalated to the upper two thirds of vagina (PTV1) 
with the SIB-VMAT strategy, after 1 year follow up of the first 
15 patients. Two dose levels were planned: Level 1 (PTV2: 
45/1.8 Gy; PTV1: 55/2.2 Gy), and Level 2 (PTV2: 45/1.8 Gy; 
PTV1: 60/2.4 Gy). All treatments were delivered in 25 
fractions. Patients were treated according to a Phase I-II 
dose-escalation study. Toxicity was scored by CTC-AE v. 3.0 
scale.  
 
Results: Sixty-six HIR-EC patients were enrolled. The Level 1 
group included 38 patients while Level 2 group included 28 
patients. Clinico-pathological characteristics of the two 
groups are reported in Table 1. All patients completed 
radiation treatment without interruption. No differences 
were found between the 2 groups in terms of skin, 
gastrointestinal and genitourinary toxicities. 
 
 
 
With a median follow up of 20 months (range 3-48 months), 
no dose limiting toxicity was reported, therefore Level 2 was 
considered as the recommended dose. Three vaginal 
recurrences were documented at 8, 14 and 19 months after 
SIB-VMAT in Level 1 group. At two-years local control was 
90.4% (Level 1), versus 100% (Level 2), while disease free 
survival was 85.6% (Level 1) versus 93.3% (Level 2); overall 
survival was 96.2% ( Level 1) versus 100% (Level 2), 
respectively. 
 
Conclusion: To date, according with this phase I-II study 
clinical results, SIB-VMAT strategy represents the standard 
adjuvant treatment in HIR-EC at our Institution. We 
established the dose of 45Gy/1.8 Gy to pelvic nodes and 60 
Gy/2.4 Gy to the upper two thirds of vagina as the 
recommended doses for further evaluation of SIB- VMAT 
approaches in this setting. 
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Purpose or Objective: Minimisation of internal organ motion 
during pelvic radiotherapy (RT) is necessary to ensure 
accurate reproducible treatment. We analysed bladder and 
rectal filling during pelvic RT and their impact on CTV 
coverage. 
 
Material and Methods: Cone beam Computed Tomography 
scans (CBCTs) taken twice weekly during 3D conformal RT 
were retrospectively analysed for 10 cervical cancer patients. 
All patients followed the departmental guidelines; empty 
bladder then drink 4 cups of water 40 minutes before 
